Genetics of primary aldosteronism

Cardiovascular Issues in Endocrinology

Volumn 43, Issue , 2014, Pages 70-78

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925728686     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000360870     Document Type: Chapter

References (28)

1. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM: Case detection, diagnosis and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 28: 93: 3266-3281.
2. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300.
3. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP: A novel form of human Mendelian hypertension featuring nonglucorticoidremediable aldosteronism. J Clin Endocrinol Metab 2008; 93: 3117-3123.
4. Choi M, Scholl UI, Yue P, Bjorklund P, Zhao BX, Nelson-Williams C, Ji WZ, Cho YS, Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G, Akerstrom G, Wang WH, Carling T, Lifton RP: K + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772.
5. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM: A chimaeric 11β-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355: 262-265.
6. Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P, Samson-Couterie B, Hahner S, Quinkler M, Fallo F, Letizia C, Allolio B, Ceolotto G, Cicala MV, Lang K, Lefebvre H, Lenzini L, Maniero C, Monticone S, Perrocheau M, Pilon C, Plouin PFO, Rayes N, Seccia TM, Veglio F, Williams TA, Zinnamosca L, Mantero F, Benecke A, Jeunemaitre X, Reincke M, Zennaro M-C: Prevalence, clinical and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension 2012; 59: 592-598.
7. Zennaro MC, Jeunemaitre X: Mutations in KCNJ5 gene cause hyperaldosteronism. Circ Res 2011; 108: 1417-1418.
8. Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Okada S, Rokutanda N, Takata D, Koibuchi Y, Horiguchi J, Oyama T, Takeyoshi I, Mori M: Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012; 97: 1311-1319.
9. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE: Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology 2012; 153: 1774-1782.
10. Azizan EAB, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ, O'Shaughnessy KM: Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension 2012; 59: 587-591.
11. Azizan EAB, Lam BYH, Newhouse SJ, Zhou JH, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ: Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculate-like tumors. J Clin Endocrinol Metab 2012; 97:E819-E829.
12. Zennaro M-C, Jeunemaitre X, Boulkroun S: Integrating genetics and genomics in primary aldosteronism. Hypertension 2012; 60: 580-588.
13. Monticone S, Namita G, Hattangady NG, Nishimoto K, Mantero F, Rubin B, Cicala MV, Pezzani R, Auchus RJ, Ghayee HK, Shibata H, Kurihara I, Williams TA, Giri JG, Bollag RJ, Edwards MA, Isales CM, Rainey WE: Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab 2012; 997:E1567-E1572.
14. Murthy M, Azizan EA, Brown MJ, O'Shaughnessy KM: Characterization of a novel somatic KCNJ5 mutation dell157 in an aldosterone-producing adenoma. J Hypertens 2012; 30: 1827-1833.
15. Akerstrom T, Crona J, Verdugo AD, Starker LF, Cupisti K, Willenberg HS, Knoefel WT, Saeger W, Feller A, Ip J, Soon P, Anlauf M, Alesina PF, Schmid KW, Decaussin M, Levillain P, Waangberg B, Peix JL, Robinson B, Zedenius J, Backdahl M, Caramuta S, Iwen KA, Botling J, Stalberg P, Kraimps JL, Dralle H, Hellman P, Sidhu S, Westin G, Lehnert H, Walz MK, Akerstrom G, Carling T, Choi M, Lifton RP, Bjorklund P: Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One 2012; 7:E41926.
16. Scholl UI, Lifton RP: New insights into aldosteroneproducing adenomas and hereditary aldosteronism: mutations in the K + channel KCNJ5. Curr Opin Nephrol Hypertens 2013; 22: 141-147.
17. Zennaro MC, Rickard AJ, Boulkroun S: Genetics of mineralocorticoid excess: an update for clinicians. Eur J Endocrinol 2013; 169:R15-R25.
18. Beuschlein F, Boulkroun S, Osswald A, Wjeland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B, Zennaro MC, Strom TM, Reincke M: Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45: 440-444.
19. Scholl UK, Goh G, Stölting G, Campos de Oliveira R, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR, Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P, Westin G, Akerström G, Björklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP: Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 2013; 45: 1050-1054.
20. Azizan EAB, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AED, Davenport AP, Dekkers T, Tops B, Kusters B, Ceral J, Yeo GSH, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ: Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055.
21. Küpers EM, Amar L, Raynaud A, Plouin PF, Steichen O: A clinical prediction score to diagnose unilateral primary aldosteronism. J Clin Endocrinol Metab 2012; 97: 3530-3537.
22. Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D, Williams TA, Einaudi S, La Grotta A, Rabbia F, Veglio F: Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (Primary Aldosteronism in TOrino-GENetic forms). Hypertension 2011; 58: 797-803.
23. Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R, Hammer LK, Harley FL, Farhi A, Wang W-H, Lifton RP: Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5 . Proc Natl Acad Sci USA 2012; 109: 2533-2538.
24. Charmandari E, Sertedaki A, Kino T, Merakou C, Hoffman DA, Hatch MM, Hurt DE, Lin L, Xekouki P, Stratakis CA, Chrousos GP: A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab 2012; 97: E1532-E1539.
25. Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL: Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin Exp Pharmacol Physiol 1992; 19: 319-322.
26. Carss KJ, Stowasser M, Gordon RD, O'Shaughnessy KM: Further study of choromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens 2011; 25: 560-564.
27. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst TJ, Okamura H: Salt-sensitive hypertension in circadian clock-deficient Cry -null mice involves dysregulated adrenal Hsd3b6. Nat Med 2010; 16: 67-74.
28. Funder JW: Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine. Integr Blood Press Control 2013; 6: 129-138.